Autopsy report · NCT05275673

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

“Sponsor decision - funding issues”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 6 months before it stopped.
• 7 participants enrolled.
• Results were posted on the registry 2 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Faeth Therapeutics

Sponsor type

Industry

Conditions

Non-Small Cell Lung Cancer; Squamous Non-small-cell Lung Cancer; Squamous Non-Small Cell Neoplasm of Lung; NFE2L2 Gene Mutation

Interventions

sapanisertib

Participants

7

Sites

14

Countries

United States

Trials that died the same way

• PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
  “sponsor decision” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.